Cabazitaxel versus docetaxel re-challenge for mCRPC (CANTATA)

• Research type

  Research Study

• Full title

  A multicentre, phase II randomised controlled trial evaluating cabazitaxel versus docetaxel re-challenge for the treatment of metastatic Castrate Refractory Prostate Cancer, previously treated with docetaxel at inception of primary hormone therapy

• IRAS ID

  113173

• Contact name

  Nicholas James

• Eudract number

  2012-003835-40

• Research summary

  The purpose of the CANTATA trial is to compare the drug cabazitaxel with the drug docetaxel in patients whose prostate cancer has prograssed despite treatment with docetaxel as part of the STAMPEDE trial. Currently, patients who are taking part in the STAMPEDE trial who have already received treatment with docetaxel would receive a second course of docetaxel if their disease prograssed. CANTATA will investigate whether the drug cabazitaxel, which has shown therapeutic potential in advanced prostate cancer, provides improved benefit in comparison with a second course of docetaxel.

• REC name

  North West - Liverpool Central Research Ethics Committee

• REC reference

  12/NW/0792

• Date of REC Opinion

  10 Dec 2012

• REC opinion

  Further Information Favourable Opinion